English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

ver the past decade, use of androgen deprivation therapy (ADT) to treat prostate cancer has risen seven-fold, from 9.8% of patients in 1989-1992 to 74.6% in 1991-2001 (1). ADT is used as neoadjuvant and adjuvant treatment with radiation therapy (RT), to treat recurrence following primary treatment with surgery or RT, or when the cancer is in an advanced stage at diagnosis. While ADT has demonstrated survival benefits, it also is associated with increases in metabolic and cardiovascular risks. Men receiving ADT have been shown to develop dyslipidemia, decreased arterial compliance, increased insulin resistance, weight gain with increased visceral fat deposition, decreased bone mineral density, decreased libido and erectile dysfunction, fatigue, cognitive changes and depression (1-12)

Staying Strong and Healthy: Minimizing Cardiovascular and Metabolic Effects of Androgen Deprivation Therapy: A Study in Transition